Amylyx Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
44.9%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$1.47next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly279.8MTarget: Sufficient to fund operations into 2028
LUCIDITY Phase 3 Trial Enrollment Quarterly78.0Target: 78 (Enrollment completed in March 2026)
Quarterly Net Loss Quarterly-41.3MTarget: Minimize cash burn while advancing pipeline
Watch Items
- LUCIDITY Phase 3 Topline Data ReadoutTrigger: Statistically significant reduction in composite Level 2 and Level 3 hypoglycemic events through Week 16Action: Initiate rapid NDA submission preparations for avexitide
- AMX0114 Phase 1 LUMINA Biomarker DataTrigger: Favorable safety profile and reduction in neurofilament light chain (NfL) levelsAction: Advance Cohort 2 analysis and plan for Phase 2 clinical development
- AMX0035 Wolfram Syndrome Week 96 DataTrigger: Sustained pancreatic beta cell function and disease stabilizationAction: Engage with the FDA to align on Phase 3 trial design
Research as of 20 Jun 2026